InvestSMART

Patrys Limited (ASX:PAB)

ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.036 0.01 (38.46%)+
Announcement
Release
20 Apr 2026 9:31AM
Price at Release
$0.026
Full Release
download
Summary
Patrys Limited has successfully raised A$3.2 million through a placement of approximately 133 million shares at A$0.024 each, supported by new and existing strategic investors. The funds will be utilized to advance the company's clinical development programme, including the injectable quetiapine program into clinical trials. The placement, managed by Templar Corporate Pty Ltd, strengthens the company's balance sheet and supports immediate clinical and regulatory milestones. Key benefits include issuing one unlisted option per four shares, exercisable at $0.048, subject to shareholder approval. Director participation will also be sought, contingent on shareholder approval.
Key Points
  • Patrys Limited has raised A$3.2 million through a successful placement.
  • Approximately 133 million shares were issued at A$0.024 per share.
  • The placement was well-supported by new and existing strategic investors.
  • The funds will be used to progress clinical trials and regulatory milestones.
  • Patrys aims to advance its injectable quetiapine program into clinical trials.
  • Shares were issued under ASX Listing Rules 7.1 and 7.1A.
  • Investors receive one unlisted option for every four shares, exercisable at $0.048.
  • Director participation is planned, subject to shareholder approval.
  • Templar Corporate Pty Ltd acted as the sole lead manager for the placement.
  • The placement strengthens Patrys' balance sheet.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.